INR:9057. marathonbet et Bristol-Myers Squibb's deucravacitinib significantly improves signs and symptoms of psoriatic arthritis Opdivo + Cabometyx combination for ...

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

A research team from the University of Central Florida's College of Medicine conducted a study of patient perceptions of ...

Characterized by chronic or cyclical pain in small and large joints, fatigue, and associated organ and other changes, treatment focuses on controlling symptoms, with an economic ... have shown promise ...

If you have brittle nails, swollen hands or unusually pale fingertips it may be more than just a damper to your manicure. It ...

The good news is that there do appeared to be proteins which clearly distinguish psoriasis from psoriatic arthritis, and ...

With a combination of early diagnosis, modern treatments, and lifestyle changes, women with arthritis can significantly improve their quality of life and manage both physical and emotional challenges.

According to study results published in RMD Open, patients with psoriatic arthritis (PsA) face a substantial risk for chronic kidney disease (CKD). Key risk factors contributing include diabetes, ...